China Pharma Holdings Cash Flow from Investing Activities 2010-2023 | CPHI
China Pharma Holdings cash flow from investing activities from 2010 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
China Pharma Holdings Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$-0 |
| 2022 |
$-0 |
| 2021 |
$-0 |
| 2020 |
$-1 |
| 2019 |
$-0 |
| 2018 |
$-0 |
| 2017 |
$-0 |
| 2016 |
$-0 |
| 2015 |
$-2 |
| 2014 |
$-7 |
| 2013 |
$-19 |
| 2012 |
$-5 |
| 2011 |
$-6 |
| 2010 |
$-11 |
| 2009 |
$-15 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.005B |
$0.007B |
|
CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings.
|
